HC Wainwright Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals (NASDAQ:AGIO) had its price objective upped by research analysts at HC Wainwright from $55.00 to $62.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright‘s price objective would suggest a potential upside of 119.31% from the company’s previous close.

Several other research firms also recently commented on AGIO. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, September 21st. Citigroup boosted their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. upped their price target on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. TD Cowen raised Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. Finally, Truist Financial cut their price objective on Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating on the stock in a research note on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $42.38.

Agios Pharmaceuticals Stock Down 9.9%

Shares of AGIO opened at $28.27 on Friday. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -4.03 and a beta of 0.66. The company’s fifty day moving average is $33.37 and its 200-day moving average is $31.75. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.15. The business had revenue of $55.39 million during the quarter, compared to analyst estimates of $51.65 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. As a group, research analysts predict that Agios Pharmaceuticals will post -5.85 earnings per share for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 7,866 shares of Agios Pharmaceuticals stock in a transaction dated Monday, October 26th. The stock was sold at an average price of $37.69, for a total value of $296,469.54. Following the transaction, the insider directly owned 54,645 shares in the company, valued at approximately $2,059,570.05. The trade was a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 9,855 shares of company stock valued at $371,112. Company insiders own 5.40% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Three Bridge Wealth Advisors LLC bought a new stake in Agios Pharmaceuticals in the 3rd quarter valued at $27,000. Jefferies Financial Group Inc. acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at $1,020,000. Lido Advisors LLC bought a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth about $411,000. Fulcrum Asset Management LLP bought a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth about $94,000. Finally, AlphaCentric Advisors LLC lifted its holdings in shares of Agios Pharmaceuticals by 3.9% during the 3rd quarter. AlphaCentric Advisors LLC now owns 14,731 shares of the biopharmaceutical company’s stock worth $490,000 after acquiring an additional 558 shares during the period.

More Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Agios reported a Q3 loss of $1.09 per share, narrower than the cited consensus estimate of $1.24, and revenue of $55.39 million, above estimates of $51.65 million. The per-share loss also improved from $1.78 a year earlier. Earnings results
• Positive Sentiment: Mitapivat revenue rose more than fourfold, highlighting growing commercial traction. Agios expects an FDA decision on mitapivat for sickle cell disease in February 2027, a potentially important future catalyst. Mitapivat sales and FDA timing
• Positive Sentiment: Agios plans to present new clinical data on mitapivat in sickle cell disease and AG-236 in polycythemia vera at the ASH 2026 meeting, offering investors additional updates on its rare-hematology pipeline. ASH 2026 data announcement
• Neutral Sentiment: The company aims to eliminate more than 100 R&D positions. The cuts could reduce costs, but investors may also consider whether a smaller research workforce affects development and execution. R&D workforce cuts
• Negative Sentiment: Despite the earnings beat, Agios remains loss-making, leaving its outlook dependent on continued product growth and successful clinical and regulatory milestones. Quarterly results and business update

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.